Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that updated clinical data for its CD20xCD3 T-cell engaging bispecific antibodies, including five oral presentations, were presented at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, December 10-13, 2022.
December 12, 2022
· 12 min read